Company Profile
Keros Therapeutics Stock Price, News & Catalysts
- Ticker:
- KROS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.36 USD (+5.77%)
Close
Last updated: September 17, 2026
209M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, KROS closed up 5.77% at $11.36. No new same-company headline was identified in the current news window.
Company overview
TGF-β Biology Platform
Keros Therapeutics develops protein therapeutics for diseases linked to dysfunctional signaling within the transforming growth factor-beta family, which regulates muscle, bone, adipose tissue, cardiac tissue, and blood-cell development.
Rinvatercept
Rinvatercept is the company’s lead internally controlled candidate and is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Elritercept Partnership
Elritercept targets cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis. Takeda has assumed development responsibility under a licensing partnership.
Future catalysts
- Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Keros Therapeutics (KROS)?
Keros Therapeutics (KROS) most recently closed at 11.36 USD, a +5.77% move versus the previous session.
What is the market cap of Keros Therapeutics (KROS)?
Keros Therapeutics currently has a market capitalization of 209M USD on BioPharmSignal.
What does Keros Therapeutics do?
TGF-β Biology Platform Keros Therapeutics develops protein therapeutics for diseases linked to dysfunctional signaling within the transforming growth factor-beta family, which regulates muscle, bone, adipose tissue, cardiac tissue, and blood-cell development. Rinvatercept Rinvatercept is the company’s lead internally controlled candidate and is being...
On which exchange is KROS stock listed?
Keros Therapeutics (KROS) is associated with NASDAQ, United States, Biopharma.
What is elritercept?
Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
Which conditions is Keros Therapeutics targeting with elritercept?
Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
How does Keros Therapeutics describe recent progress with elritercept?
Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
What is Biology?
TGF-β Biology Platform Keros Therapeutics develops protein therapeutics for diseases linked to dysfunctional signaling within the transforming growth factor-beta family, which regulates muscle, bone, adipose tissue, cardiac tissue, and blood-cell development.